Kite Pharma

YESCARTA

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Kite Pharma

Yescarta HCPCS:

Q2041

HCPCS Code Descriptor:

Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Category:

Q Code

Yescarta NDCs:

71287-0119-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Bag

Route of Administration:

Intravenous

Yescarta CPT Codes:

Potential CPT administration codes for Yescarta can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Yescarta:

YESCARTA is an Oncology drug manufactured by Kite Pharma and administered via the Intravenous route of administration. The Q Code: Q2041 is aligned to the drug YESCARTA.

ACCESS PRICING AND MORE BY REGISTERING

Q2041 Added Date:

April 1, 2018

Q2041 Effective Date:

January 1, 2019

Q2041 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Yescarta billing and coding information.
Yescarta patient assistance information can be found through Kite Konnect at the URL: https://www.kitekonnect.com/
YESCARTA prescribing information can be found at the link below:
Information regarding YESCARTA’s side effects can be found at MedlinePlus